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Importance: Accurate and reliable assessment of pulmonary congestion is important for 
describing baseline characteristics and estimating acute decompensated heart failure (ADHF) 
patient risk in population studies. 
Objective: This systematic review aims to determine prevalence and methods of assessing 
pulmonary edema in studies enrolling ADHF patients. 
Methods: PubMed and Embase were searched from January 2009 to April 2019 to identify 
studies based on large heart failure registries. Prevalence of ADHF and methods of determining 
pulmonary edema were abstracted and summarized. The NIH Quality Assessment Tool was used 
for assessing risk of bias. 
Findings: Eight prospective, inpatient, large (N≥1000) heart failure registries were included; all 
were set in Europe or the US. Although most studies reported using either physical exam or chest 
radiography for assessment, specific criteria were not generally reported. The prevalence of 
pulmonary congestion among ADHF patients was imprecise and ranged from 3% to 74%. 
Conclusions and Relevance: Large ADHF registries are not consistent at measuring and 
reporting pulmonary congestion. Use of standardized methods could better estimate the 
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Acute decompensated heart failure (ADHF) is a leading cause of hospitalization in 
patients over 65 years of age. Despite declining in-hospital mortality, 35-40% of patients in the 
United States and 20-40% in Europe die within a year after discharge1-3. Although increased 
survival rates have been seen over the past four decades with advances in pharmacotherapy and 
device treatment of heart failure with reduced ejection fraction (HFREF), prevalence of heart 
failure continues to rise, especially heart failure with preserved ejection fraction (HFPEF)1,2. 
Despite advances in treatment, increasing heart failure prevalence of contributes to high 
hospitalization rates and, consequently, high health care costs.3,4 Patients hospitalized with 
ADHF remain at high risk of both inpatient and post-discharge morbidity and mortality. 
Therefore, improved diagnosis, monitoring and novel interventions for patients with ADHF 
represents an important current and future research need.2 From a public health perspective, the 
timely and accurate definition, identification and characterization of patients with ADHF is 
essential for the successful management of population-based heart failure research.4 
ADHF is diagnosed on the basis of finding a constellation of clinical symptoms and 
signs, supported by a diagnostic approach that includes laboratory testing and imaging.5 The 
presence of pulmonary edema is common in ADHF and has been often used as an entry criterion 
for heart failure studies.6 Clinical evidence of pulmonary edema includes rales or crackles on 
auscultation and findings of pulmonary congestion and/or pleural effusion on chest radiography.6 
Newer, more objective methods of assessing pulmonary edema include pulmonary ultrasound, 
bioimpedance measurement and remote dielectric sensing (ReDS).12 However, these are not 
routinely used in the diagnosis or monitoring of pulmonary edema in population studies.7-12  
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Regardless of whether pulmonary edema is assessed qualitatively using physical exam or 
imaging, or quantitatively using newer technology, the methods of measurement and criteria to 
assess pulmonary edema within large epidemiological studies is important to gain a better 
understanding of its prevalence in ADHF patients. Consistent methods across studies also 
improves the ability to compare findings. Since severe pulmonary edema with ADHF is 
associated with a greater mortality risk and rate of hospital readmissions, it is critical to assess 
pulmonary edema in a systematic and reproducible manner.13 Accurate and reliable assessment 
of pulmonary congestion is important for describing baseline characteristics and estimating 
ADHF patient risk in population studies and in the community, and can be a potentially 
meaningful outcome in population studies.14 
Objectives 
There has been one previous systematic review without meta-analysis which was 
published in 2015 that has examined the prevalence and methods of assessment of pulmonary 
edema in ADHF patients. However, the authors only searched for clinical trials with literature 
review from 2002-2013.14 To date, there has not been a systematic review examining the 
prevalence and methods of assessment of pulmonary edema in large epidemiological studies and 
heart failure registries. Trials often have narrow inclusion criteria tailored to the intervention 
being studied. Heart failure registries, however, provide important information on ADHF 
prevalence, burden, and natural history. This systematic review aims to assess and report the 






Reporting guidelines from the PRISMA 2009 checklist for systematic reviews were 
followed, as noted in Appendix E, Table E1. No registered review protocol exists. 
Eligibility Criteria  
Eligibility criteria were established a priori, as detailed in Appendix B, Table B1. 
Inclusion criteria specified adult patients with ADHF. Specifically, definite ADHF is defined as 
a new onset (de novo) or worsening of a confirmed diagnosis of heart failure based on a 
combination of a history and physical, imaging, laboratory data, and/or procedures such as 
electrocardiography or echocardiography, etc., with diuresis as a main treatment for improving 
symptoms, with no other comorbidities to primarily account for the acute presentation. This 
definition is based on ARIC Heart Failure Classification criteria4. 
Empirical study designs that were included were intended to capture large heart failure 
registries in the United States and Europe. The rationale was for better population estimation of 
pulmonary edema among ADHF patients with comparability among Western nations. These are 
mainly multi-center, prospective and retrospective cohort studies with at least 1000 registered 
patients.  
Studies occurring in the inpatient and outpatient settings were included. Studies that 
occurred only in the prehospital or EMS setting were not included. Studies that primarily focus 
on a singular incitant of ADHF (i.e. acute myocardial infarction, severe hypertension, drug-
induced, iatrogenic causes, stress (Takotsubo) cardiomyopathy, etc.) were excluded. Studies that 




Additionally, studies that diagnosed acute heart failure solely based on symptoms alone, 
solely based on physical exam that did not include the presence of crackles or rales, and solely 
based on laboratory data that did not include B-type natriuretic peptide (BNP) and/or N-terminal 
pro-BNP were excluded. Studies that only examined chronic heart failure without exacerbation 
were excluded. Studies that involved pregnant women or peripartum cardiomyopathy were 
excluded. Finally, studies that did not have any indication of a measurement or prevalence of 
pulmonary edema or congestion in their study population were excluded. 
Literature Search Strategy 
The electronic databases PubMed and Embase were searched from January 1, 2009 to 
April 12, 2019. Basic search eligibility requirements included English language studies 
published in peer-reviewed journals. Search terms were related to acute decompensated heart 
failure and pulmonary edema.  A full search strategy with complete search terms for these 
databases can be found in Appendix C, Table C1. Additionally, ClinicalTrials.gov was also 
searched for grey literature, specifically for unpublished studies with complete results, with the 
search term, “acute decompensated heart failure”. There were no completed studies with 
unpublished results. 
Study Selection Process 
Once the search strategy was complete, articles were extracted from their respective 
databases and organized using EndNote X915, with duplicate articles deleted during organization. 
Abstracts from EndNote X9 were exported then imported into Covidence software16 for initial 
article screening by the author. The articles were first screened by title and abstract, then by 
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review of obtained full text articles, using eligibility criteria established a priori noted previously. 
The study selection process noted in the PRISMA Flow Diagram in Appendix D, Figure D1. 
Data Extraction Process    
Data extraction was performed using standardized collection forms, as noted in Appendix 
A, Tables A1, A2, and A3, to ensure complete and relevant collection. 
Abstracted study characteristics included ADHF sample size, geographical region/setting, 
gender, age, left ventricular ejection fraction (LVEF) by echocardiography, systolic blood 
pressure, relevant laboratory values (BNP, NT-ProBNP, creatinine), and history of COPD. All of 
the aforementioned study characteristic items were at study baseline, which was generally at 
admission into the hospital. 
Methods for assessing pulmonary congestion in ADHF patients in these studies were also 
extracted. Specifically, it was noted whether or not pulmonary congestion was measured with 
physical exam and/or chest radiography, and if so, which criteria were used for each method. 
Prevalence of pulmonary congestion in ADHF patients was extracted based on both 
physical exam and chest radiography findings, and overall ADHF pulmonary congestion 
prevalence was determined using these findings and other available reported data from the study 
(i.e. European Society of Cardiology (ESC) acute pulmonary edema classification, etc.). All 
methods of assessment and values for prevalence were also at study baseline at the beginning of 
the patients’ hospital admissions. For determining overall prevalence of pulmonary edema at 
baseline within each study, these values were reported in Appendix A, Table A3 as highest 
percentage available within the study.  
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Given the clinical and methodological heterogeneity in the assessment methods as well as 
the reporting of pulmonary congestion in the reviewed studies, a meta-analysis of the reviewed 
data could not be performed. No additional analyses were performed. 
Risk of Bias in Individual Studies 
Individual study risk of bias and overall quality of each study was assessed, as noted in 
Appendix A, Table A4, using the National Institutes of Health (NIH) Quality Assessment Tool 
for Observational Cohort Studies.17 
Risk of Bias Across Studies 
Risk of bias across studies and overall strength of evidence was difficult to assess, given 
the clinical and methodological heterogeneity. It was instead analyzed from the perspective of 
potential publication bias and possible selective reporting within studies. Reporting within 
studies was generally compared to determine if information normally presented in the majority 
of included studies were excluded and, if so, if the authors had justification for its absence. 
Results: 
Study Selection  
Database searches identified 935 articles. After duplicate removal, 699 unique articles 
were left for screening. There was one additional record identified through hand-searching 
included studies not captured by our search strategy, totaling 700 articles available for screening. 
After using eligibility criteria to screen by title and abstract, 669 articles were determined to be 
irrelevant. The remaining 31 were screened with full text review. After using eligibility criteria 
to screen during full text review, 11 articles reporting on 8 studies met full eligibility criteria. 
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The most common reasons for exclusion of full text articles were wrong study design, inadequate 
sample size, and wrong outcomes. Appendix D, Figure D1 is the PRISMA Flow Diagram which 
describes the flow for article screening in this systematic review, including reasons for full-text 
exclusion. 
Study Characteristics 
The characteristics of the studies for review are shown in Appendix A, Tables A1. Eight 
large prospective heart failure registries with ADHF patients were eligible for data extraction 
after article screening. Only one study was from the United States.23 The other seven studies 
were from Europe, with three of the seven involving multiple European countries19,21,22,25 
compared to the other four studies which examined one country (Czech Republic27, Italy26,28, 
Romania18,20, and Spain24, respectively). Study sample size across studies ranged from n = 1838 
to 99,825 patients. All of the study populations came from the inpatient setting; patients were 
most likely recruited at admission into the hospital for symptoms of ADHF. The study 
populations were all predominantly male except for one.24 The age of the patients in the 
registries ranged from 68.5 to 80.0 years. Left ventricular ejection fraction was typically low in 
the mid to high 30%. Systolic blood pressure ranged from 130-138 mm Hg across the studies, 
with the majority of patients presenting with a history of hypertension. BNP / NT-ProBNP was 
only reported in five of the eight studies, and those that did report them only had values for 50% 
or less of their study population. In general, BNP / NT-ProBNP were elevated across these 
studies. Creatinine levels were elevated across all studies from 1.2 to 1.3 mg/dL. A positive 
history of COPD was reported across the studies for 19% - 35.49% of the study population. 
It should be noted that the ESC-HF Pilot study and the ESC-HF-LT study are by the same 
investigator team. The ESC-HF Pilot study was a precursor to the ESC-HF-LT in terms of 
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methods used, but each had two different study populations at two different time periods which 
is why both studies were included for analysis. 
The NIH Quality Assessment Tool for Observational Cohort Studies was used to 
assessing risk of bias. The quality ratings for each study is noted in Appendix A, Table A4. The 
included studies in general had a good quality rating with a low risk for bias, with the exception 
of two studies which received fair ratings with a low to medium risk of bias. Across the studies, 
there was limited selection and measurement bias. For the two studies that received fair ratings, 
the ESC-HF Pilot and EAFHE studies, respectively, there was some bias for confounders in each 
study, explained below in Risk of Bias Across Studies. 
For each included study, while there was overall limited measurement bias, the 
measurement of pulmonary edema in the included studies was not clearly defined, equal, valid, 
and reliable based on reporting, with the exception of the RO-AHFS study which specified 
physical exam criteria, and the EAHFE study which briefly specified chest radiography criteria. 
Methods of Assessment of Pulmonary Congestion 
Methods for assessing pulmonary congestion in ADHF patients in these studies were 
examined. These results are noted in Appendix A, Table A2. Four out of the eight studies 
reported explicitly using both physical exam and chest radiography findings to assess pulmonary 
edema.18-22,27 One study reported solely using physical exam findings for assessment,26,28 and one 
study reported only using chest radiography.24 The remaining two studies did not describe 
methods for assessing congestion but still reported a prevalence.23,25 
For the five studies that reported using physical exam findings, each study used 
rales/crackles as the primary physical exam finding, but only one out of the five studies specified 
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criteria for what degree of rales would classify as pulmonary edema. The RO-AHFS (2011) 
study reported that rales more than ½ of the lung fields was considered pulmonary congestion. 
For the five studies that reported using chest radiography findings, only two studies 
explicitly reported any kind of criteria. One study was non-specific, only listing “pulmonary 
congestion” as a finding. The other study, EAHFE (2018), was more specific and listed “lung 
interstitial edema” and “lung alveolar edema” as criteria for pulmonary congestion. 
Prevalence of Pulmonary Congestion 
For the prevalence of pulmonary congestion, these results are noted in Appendix A, 
Table A3. Only two out of the five studies that reported using physical exam reported a 
prevalence based on rales or crackles, The ESC-HF-LT study reported a prevalence of 73.6%, 
and the IN-HF study reported a prevalence of 78%. Additionally, only two out of the five studies 
that reported using chest radiography reported a prevalence based on presence of pulmonary 
edema or vascular congestion. The ESC-HF-LT study reported a prevalence of 73.6%, and the 
EAFHE study reported a prevalence of 58.6% for those with lung interstitial edema and 9.3% for 
those with lung alveolar edema. 
Synthesizing estimates of overall prevalence of pulmonary congestion from included 
studies was difficult because some studies may have reported pulmonary edema in terms of ESC 
clinical classification. According to ESC 2008 Guidelines, acute pulmonary edema as a clinical 
classification of acute heart failure syndrome (AHFS) is characterized as severe breathlessness at 
rest with crackles or rales over lungs, effusion tachycardia, and tachypnea.29 This is considered 
to be a different clinical classification from acute decompensated heart failure, which is its own 
clinical class under ESC criteria, due to the severity of the pulmonary edema. Four out of the 
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eight studies (EHFS II, ESC-HF-Pilot, ESC-HF-LT, and RO-AHFS) reported acute pulmonary 
edema as a separate clinical class similar to the ESC classification system. However, the specific 
measurement of acute pulmonary edema for these classification purposes in these studies were 
not reported. Only one out of those four studies (ESC-HF-LT study) also reported pulmonary 
congestion due to physical exam and chest radiography separate from the ESC classification, 
which is important since pulmonary congestion can be present in the absence of tachycardia and 
tachypnea.  
For the ESC-HF-LT study, prevalence based on physical exam and chest radiography is 
reported above, but based on ESC clinical classification, the prevalence of acute pulmonary 
edema was 13.2%. For the other three studies which reported acute pulmonary edema as a 
separate clinical class similar to the ESC classification system, the EHFS II, ESC-HF-Pilot, and 
RO-AHFS studies, the prevalence of acute pulmonary edema based on ESC clinical 
classification was 13.3%, 16.0%, and 28.7%, respectively. For the EHFS II study, this was the 
only reported prevalence of pulmonary edema within the study. For the ESC-HF-Pilot study, an 
additionally reported prevalence of 62% was based on all ADHF patients who presented with 
pulmonary congestion. However, the method of assessment of pulmonary congestion was not 
reported in this study. For the RO-AHFS study, the method of assessment of pulmonary 
congestion was also not reported. However, a prevalence of 60.5% was calculated based on 
reported percentages of those with pulmonary congestion among their ADHF population, with 
59% of those with ADHF with LVEF <45% (n = 1125), and 64.8% of those with ADHF with 
LVEF >45% (n = 383) having pulmonary congestion. This calculated prevalence is considered 
the overall prevalence for this study. 
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The other four studies (GWTG-HF, AHEAD, IN-HF, and EAHFE) did not report acute 
pulmonary edema as a separate clinical class similar to the ESC classification system. The IN-
HF and EAFHE studies’ overall prevalence of pulmonary congestion are based on either the 
highest reported prevalence based on physical exam or chest radiography, noted above. The 
GWTG-HF reported two different percentages for prevalence, both not related to physical exam 
or chest radiography criteria and without any other specification of its assessment. Reported 
prevalence was 3.42% based on pulmonary congestion, which is considered the overall 
prevalence for this study, and 2.27% if based on acute pulmonary edema that was not specified 
and not related to ESC classification. The AHEAD study reported an overall prevalence of 
pulmonary congestion at 18.6%. Although this study did report using crackles on physical exam 
and chest radiography, it did not specify any specific criteria for exam and imaging, and it did 
not report prevalence based on physical exam or chest radiography. The specific origin of this 
prevalence of 18.6% is unclear as there is no other reported specification of its assessment. 
Additional Analysis  
- No additional analyses were done. 
 
Discussion: 
Summary of Evidence 
The large ADHF registries in this review were not consistent at measuring and/or 
reporting pulmonary edema or congestion. Two out of the eight studies did not report at all how 
they measured pulmonary congestion within their registries. For the other six studies that did 
report using either physical exam and/or chest radiography for assessment of pulmonary edema, 
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specific criteria for its assessment was not generally reported. Any methods for assessment of 
pulmonary edema outside of physical exam and chest radiography were not used in these heart 
failure registries. Across all of the included heart failure registries, measurement of pulmonary 
edema was not consistent or standardized. 
In addition, with some studies using the ESC classification criteria for acute pulmonary 
edema without physical exam, chest radiography, or specific criteria, it was difficult to obtain an 
accurate classification of a) what constitutes pulmonary edema, and b) what constitutes acute 
decompensated heart failure. Absence of restricting criteria for pulmonary congestion may have 
resulted in inconsistent classification and overlap between the ESC acute pulmonary edema 
classification and other ESC clinical classifications of AHFS (i.e. ADHF, cardiogenic shock, 
hypertensive heart failure, etc.,), leading to lower reported prevalence of pulmonary edema. 
Other studies grouped and analyzed AHFS together and did not separate the syndromes, which 
makes it difficult for comparison with studies that do separate the classifications. Without 
consistent criteria for either pulmonary congestion or ADHF across these studies, it is difficult to 
compare and contrast and to have an accurate and precise estimation of the prevalence of 
pulmonary edema in this population. Based on the included studies in this review, the prevalence 
of pulmonary congestion among ADHF patients in Western countries within United States and 
Europe imprecisely ranges from about 3% to 74%. 
The ability to have standardized definitions of both ADHF and pulmonary congestion 
across larger studies, as well as standardized assessment of pulmonary edema would most likely 
result in better estimation of prevalence of pulmonary edema within the ADHF population. This 
is important for better estimating patient risk, in-hospital and post-discharge mortality in the 
ADHF population among those exposed to pulmonary congestion. 
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Lastly, based on this pre-defined search, there is only one recent study investigating 
pulmonary edema or congestion prevalence status in acute heart failure patients from United 
States heart failure registries within the past 10 years. During abstract screening and review, 
there are sub-analyses from United States studies looking at other factors and exposures within 
AHF patients, but pulmonary edema within this population was not of interest. In the future, 
there needs to be more studies/registries in the United States that regularly report the prevalence 
of pulmonary edema within ADHF patients. 
Limitations 
For the risk of bias across studies, the risk of publication bias is potentially present in 
terms of studies not being published due to null or non-significant results. Given that this search 
captured large heart failure registries with overall longitudinal data collection, the chance of a 
large-scale registry comparable to the eight included studies not being reported or published due 
to null or unexpected results is not likely. The chance of a similar large-scale prospective study 
not captured in the pre-determined search strategy is also unlikely. 
However, there appears to selective reporting of pulmonary edema within studies. 
Specifically, as noted above, there were a few studies that appeared to mainly use the ESC 
clinical class of acute pulmonary edema which is typically reserved for more severe pulmonary 
edema and make associations with outcomes such as all-cause mortality without making the 
same associations for those who may have pulmonary congestion present but do not classify for 
acute pulmonary edema based on ESC classification. Also, the studies that solely report acute 
pulmonary edema based on ESC classification without other reporting of pulmonary congestion 
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tended to underreport pulmonary congestion in their studies which could also bias any 
associations with measured outcomes. 
For the two studies that received fair ratings in the NIH Assessment, the ESC-HF Pilot 
and EAFHE studies, respectively, there was some bias for confounders in each study. Neither 
study did an adjusted multivariate for their mortality outcome in association with major 
exposures in their studies for their ADHF patients and thus their reported mortalities should be 
interpreted cautiously. For the ESC-HF Pilot study, the authors explained that all-cause mortality 
was not adjusted statistically due to the pilot study’s limited number of deaths and the short 
length of the study (7 months). This was addressed in the later version of the study, the ESC-HF-
LT study, which had much more longitudinal data for each patient at 3 months and 1 year. For 
the EAFHE, there was no apparent justification for the lack of statistical adjustment of its 
mortality outcome. Every other study reported an adjusted mortality statistic based on reasonable 
exposures with potential for confounding. 
Also, in addition to the characterization of pulmonary edema among these patients, 
although these registries provide important epidemiological data on acute heart failure, they fail 
to accurately characterize the population of patients with ADHF due to either a lack of uniform 
diagnostic criteria across different studies and even different sites within studies. With 
improvement in consistent training protocols for pulmonary edema within sites and across 
studies, the characterization of ADHF patients will also improve. 
In terms of limitations of this review, given the clinical and methodological heterogeneity 
in the assessment methods for pulmonary congestion as well as the reporting of pulmonary 
congestion in the reviewed studies, a meta-analysis of the reviewed data could not be performed. 
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With improved standardized assessment, criteria, and reporting of pulmonary congestion within 
ADHF patients in these large heart failure registries, there will be improved pooling of data. 
Conclusions 
Large epidemiological registries and studies for acute decompensated heart failure are not 
consistent at measuring and/or reporting pulmonary edema or congestion. There needs to be a 
standardized method to measure pulmonary edema across large studies for better estimation of 
prevalence of pulmonary edema in acute heart failure patients. 
Future studies and systematic reviews should focus on registries/large studies with 
follow-up throughout hospitalization from admission to discharge as well as post-hospitalization 
and follow degree of improvement of pulmonary edema during those time periods with 
associated pharmacological and interventional therapy. In addition to this, with better 
standardization of assessment of pulmonary edema, future systematic reviews should examine 
the pooled association between pulmonary congestion and mortality as well as rehospitalization 
rates in the inpatient and post-discharge settings. 
Finally, with the recent rise in newer quantitative methods and improved technology to 
assess pulmonary edema, a reliable standard and quantitative method of measuring pulmonary 
edema in ADHF patients is hopefully in the near future. 
Funding: 













Table A1. Characteristics of Prospective Heart Failure Cohort Studies
 
Abbreviations: NR = Not Reported; SD = Standard Deviation; IQR = Interquartile Range; LVEF = left ventricular ejection fraction; 
SBP = systolic blood pressure; COPD = chronic obstructive pulmonary disease 





Table A2. Methods of Assessing Pulmonary Congestion in Acute Decompensated Heart Failure Patients 
  
















































congestion N/A NR N/A
Pulmonary 
congestion 
(non-specific) NR N/A NR
Lung 
interstitial 






Table A3. Prevalence of Pulmonary Congestion in Acute Decompensated Heart Failure Patients
 
Abbreviations: NR = Not Reported; N/A = Not Applicable; CXR = chest X-ray or chest radiography; ADHF = acute decompensated 
heart failure 
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with eligibility criteria 
prespecified and 
applied uniformly? Yes Yes Yes Yes Yes Yes Yes Yes
Sample Size 
Justification, 
Power Description, or 
Variance and Effect 
Estimates Provided? No No No No No No No No
Exposure(s) of Interest 
Measured Prior to 
Outcome(s) Being 
Measured? Yes Yes Yes Yes Yes Yes Yes Yes
Sufficient Timeframe to 
Reasonably Expect to 
See An Association 
Between Exposure and 
Outcome If It Existed? Yes Yes No Yes Yes Yes Yes Yes
Exposure as Categorical 
or Continuous Variable? Categorical CategoricalCategorical Categorical CategoricalBoth Both Both
Exposure Meausres 
Clearly Defined, Equal, 
Valid, and Reliable? Yes Yes Yes Yes Yes Yes Yes Yes
Exposure Assesed More 




and Reliable? Yes Yes Yes Yes Yes Yes Yes Yes
Investigators Blinded to 
Exposure Status of 
Participants? No No No No No No No No
Loss to follow-up after 




statistically for impact 
on relationship 
between exposure and 
outcome? Yes Yes No Yes Yes Yes Yes No
Quality Rating (Good, 
Fair, or Poor) Good Good Fair Good Good Good Good Fair
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APPENDIX B: ELIGIBILITY CRITERIA 
 
Table B1. Eligibility Criteria in PEO* Format 
 
*PEO = Population, Exposure, Outcome format, as opposed to the traditional PICO (Population, 
Intervention, Comparison, Outcome) format.  




 Adult US and European patients 18 
years and older 
 Acute decompensated heart failure 
(ADHF) (both de novo and worsening 
of chronic HF) based on a combination 
of H&P, imaging, labs, and/or 
procedures, with diuresis as a main 
treatment for improving symptoms, with 
no other comorbidities to primarily 
account for presentation 
 Non-US or European patients 
 Less than 18 years old 
 Studies that primarily focus on one 
incitant of ADHF (i.e. acute MI, severe 
hypertension, drug-induced, iatrogenic 
causes, stress (Takotsubo) 
cardiomyopathy) 
 Studies that primarily focus on acute 
pulmonary edema (APE) 
 Suspected or possible AHF (want 
definitive diagnosis) 
 Chronic heart failure without exacerbation 
 Pregnant women 
Exposure  Tests to Measure Pulmonary Congestion 
 Physical Exam (must have present 
crackles/rales) 
 Imaging Modalities (ultrasound, CXR, 
CT) 
 Anything else that is found during the 
review (novel technology, etc.) 
  
 Studies that solely diagnose HF based on 
symptoms alone 
 Studies that solely diagnose HF based on 
physical exam that does not include 
present crackles or rales 
 Studies that solely diagnose HF based on 
labs that do not include B-type natriuretic 




 Primary outcome – Overall prevalence 
of pulmonary edema / congestion in 
ADHF patients 
 Secondary outcomes: 
 Prevalence of pulmonary edema 
based on 1) physical exam, 2) 
imaging, and 3) any other testing 
 Studies that do not indicate a prevalence 
of pulmonary edema or congestion in 
their study population 
Timing 
  
 All studies Jan 2009 and after 
(capturing 10+ years) 
 Studies before Jan 2009 
Setting(s) 
  
 Hospitalized patients / inpatient 
 Non-hospitalized patients / outpatient 
 Prehospital setting / EMS 
Study Design(s) 
  
 Prospective and retrospective cohort 
studies 
 Multi-center studies 
 Sample size greater than or equal to 
1000 participants 
 Systematic reviews +/- meta-analyses 
 RCTs / controlled clinical trials 
 Cross sectional studies 
 Case-control studies 
 Case studies / series / reports 
 Pilot studies 
 Background reviews 
 Comments, editorials, letters, or news 
articles 
 Single center studies 
 Sample size less than 1000 participants 
Language 
  




APPENDIX C: SEARCH STRATEGY 
 
Table C1. Search Strategy for PubMed and Embase 
PubMed – April 12, 2019 
Search Query Results 
#1 (heart failure[tiab] AND (decompensated[tiab] OR decompensation[tiab] OR 
acute[tiab]))  
29522 
#2 (Pulmonary Edema[mh] OR pulmonary edema[tiab] OR pulmonary edemas[tiab] 
OR pulmonary oedema[tiab] OR pulmonary congestion[tiab] OR rales[tiab] OR 
crepitations[tiab] OR crackles[tiab] OR lung fluid[tiab] OR wet lung[tiab] OR wet 
lungs[tiab] OR cardiogenic edema[tiab] OR cardiogenic oedema[tiab] OR 
cardiogenic congestion[tiab]) 
29282 
#3 #1 AND #2 1277 
#4 #3 AND ( "2009/01/01"[PDat] : "2019/12/31"[PDat] )  568 
#5 #4 AND (English[lang]) 519 
#6 #5 NOT (animals [mh] NOT humans [mh])  496 






((((((((((((heart failure[tiab] AND (decompensated[tiab] OR decompensation[tiab] 
OR acute[tiab])))) AND ((Pulmonary Edema[mh] OR pulmonary edema[tiab] OR 
pulmonary edemas[tiab] OR pulmonary oedema[tiab] OR pulmonary 
congestion[tiab] OR rales[tiab] OR crepitations[tiab] OR crackles[tiab] OR lung 
fluid[tiab] OR wet lung[tiab] OR wet lungs[tiab] OR cardiogenic edema[tiab] OR 
cardiogenic oedema[tiab] OR cardiogenic congestion[tiab])))) AND ( 
"2009/01/01"[PDat] : "2019/12/31"[PDat] )))) AND (English[lang]))) NOT ((animals 
[mh] NOT humans [mh])))) NOT ((comment[pt] OR commentary[ti] OR 
editorial[pt] OR editorial[ti] OR letter[pt])) 
490 
Embase – April 12, 2019 
Search Query Results 
#1 (((decompensated OR acute OR decompensation) NEXT/5 (heart-failure)):ab,ti) 20200 
#2 (‘lung edema’/exp OR (pulmonary-edema OR pulmonary-edemas OR pulmonary-
oedema OR pulmonary-congestion OR rales OR crepitations OR crackles OR lung-
fluid OR wet-lung OR wet-lungs OR cardiogenic-edema OR cardiogenic-oedema 
OR cardiogenic-congestion):ab,ti) 
55153 
#3 #1 AND #2 1644 
#4 #3 AND [2009-2019]/py  1295 
#5 #4 AND [english]/lim 1240 
#6 #5 NOT ('animal'/exp NOT 'human'/exp) 1209 




(((decompensated OR acute OR decompensation) NEXT/5 'heart failure'):ab,ti) 
AND ('lung edema'/exp OR 'pulmonary edema':ab,ti OR 'pulmonary edemas':ab,ti 
OR 'pulmonary oedema':ab,ti OR 'pulmonary congestion':ab,ti OR rales:ab,ti OR 
crepitations:ab,ti OR crackles:ab,ti OR 'lung fluid':ab,ti OR 'wet lung':ab,ti OR 'wet 
lungs':ab,ti OR 'cardiogenic edema':ab,ti OR 'cardiogenic oedema':ab,ti OR 
'cardiogenic congestion':ab,ti) AND [2009-2019]/py AND [english]/lim NOT 





APPENDIX D: PRISMA FLOW DIAGRAM 
 











Records identified through 
database searching 



























Additional records identified 
through other sources 
(n = 1) 
Records after duplicates removed 
(n = 700) 
Abstracts screened 
(n = 700) 
Abstracts excluded 
(n = 669) 
Full-text articles assessed 
for eligibility 
(n = 31) 
Full-text articles excluded, 
with reasons 
(n =  20) 
6 Wrong study design 
4 Inadequate sample size 
4 Wrong outcomes 
3 Wrong patient 
population 
2 Article not available 
1 Wrong timing 
 11 articles (8 studies) 
included for qualitative 
and quantitative synthesis 
Template From:  Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and 
Meta-Analyses: The PRISMA Statement. PLoS Med 6(7): e1000097. doi:10.1371/journal.pmed1000097 
For more information, visit www.prisma-statement.org. 
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